From: Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
City | Originator brand | Lowest-priced generic | Lowest-priced similar | ||||||
---|---|---|---|---|---|---|---|---|---|
n1 | MPR2(min—max) | Availability (SD)3 | n | MPR (min—max) | Availability (SD) | n | MPR (min—max) | Availability (SD) | |
Porto Alegre | 23 | 17.06 (2.70–94.58) | 57.6% (37.6%) | 21 | 9.97 (0.93–34.36) | 63.3% (28.6%) | 18 | 15.61 (3.17–37.87) | 54.4% (33.1%) |
Santa Cruz do Sul | 18 | 25.99 (2.60–87.57) | 57.6% (30.1%) | 11 | 9.88 (0.85–37.76) | 68.8% (22.8%) | 23 | 18.34 (1.88–32.49) | 39.2% (32.8%) |
Caxias do Sul | 17 | 30.63 (2.70–94.68) | 58.0% (23.3%) | 25 | 11.33 (0.93–48.92) | 71.2% (25.6%) | 14 | 12.40 (1.86–37.48) | 47.2% (30.4%) |
São Leopoldo | 15 | 29.40 (4.90–66.45) | 48.4% (28.3%) | 17 | 8.42 (0.85–33.93) | 65.6% (26.3%) | 17 | 8.18 (2.75–38.82) | 52.0% (31.6%) |
Pelotas | 35 | 19.08 (2.70–107.47) | 75.6% (26.9%) | 34 | 9.76 (0.87–48.95) | 85.6% (25.3%) | 10 | 9.36 (2.94–22.37) | 41.2% (27.5%) |
Bagé | 46 | 16.73 (1.32–162.53) | 91.0% (15.7%) | 39 | 9.55 (0.36–49.82) | 88.4% (20.6%) | 20 | 8.81 (1.26–36.45) | 54.8% (33.3%) |
All | 49 | 18.66 (1.36–168.41) | 64.8% (22.8%) | 42 | 11.32 (0.84–54.94) | 73.8% (18.8%) | 45 | 8.60 (1.11–38.84) | 48.1% (26.8%) |